Evidence map›Paper›PMID 40855628›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8

Liwen Wang, Linzhi Xie, Yi Zhou, Shiming Tan, Yan Yu, Qin Zhang, Xuefeng Chen, Yuhan Yan, Ruiheng Luo, Han Xiao and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Liwen WangDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Linzhi XieDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Yi ZhouDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Shiming TanDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Yan YuDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Qin ZhangDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Xuefeng ChenDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Yuhan YanDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Ruiheng LuoDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Han XiaoDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Qian ChengDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Jian ZhangDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Ying LiDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Erhua WangDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Tiebin JiangDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Jing LiuDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.
Xin LiDepartment of Hematology, Third Xiangya Hospital, Central South University, Changsha, Hunan Province, 410013, China.ORCID https://orcid.org/0000-0001-9024-7522

Funding

National Natural Science Foundation of China 81870165National Natural Science Foundation of China 82170204
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment of many solid tumors. Still, their effectiveness in multiple myeloma (MM) remains underwhelming, highlighting the need to explore alternative approaches beyond conventional ICIs. Here, CD161 is identified as a novel inhibitory receptor on bone marrow (BM) tissue resident memory CD8

Indexed as

Bone MarrowCD8-Positive T-LymphocytesMultiple MyelomaNK Cell Lectin-Like Receptor Subfamily BAnimalsHumansMiceTumor MicroenvironmentNK Cell Lectin-Like Receptor Subfamily Bbone marrow microenvironmentCD161multiple myelomatissue resident memory T cells

Identifiers

PMID40855628
PMCPMC12622403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.